Tai Ju Hwang
Tai Ju Hwang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Hoon Kook
Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, Korea
3 shared publications - Chan Jong Kim
Department of Pediatrics, Chonnam National University Medical School and Children’s Hospital, Gwangju, Korea
2 shared publications - Hee Jo Baek
Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun-gun 58128, Jeollanam-do, Republic of Korea
2 shared publications June Seung Sung
Department of Pediatrics, Chonnam University Medical School, Gwangju, Korea
2 shared publicationsBin Cho
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Korea
1 shared publication- Boram Park
Medical Department, Pfizer Pharmaceuticals Korea Ltd., Seoul 04631, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 26 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4555
Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX
Introduction: In Haemophilia B, guideline-level factor IX (FIX) prophylaxis is recommended, but real-world dosing and adherence vary. Aim: To assess treatment patterns, adherence, FIX dosing, and their associations with bleeding events in Korean patients. Methods: We conducted a retrospective chart review and one-time survey of 130 Korean patients with haemophilia B treated with FIX for ≥12 months at 12 centers (June 2022–May 2023). A total of forty-seven patients (36.2%) received prophylaxis (≥90 IU/kg/week for ≥45 weeks); the remainder were managed non-prophylactically. Annualized bleeding events (ABEs) were analyzed using negative binomial regression, and monthly bleeds with a generalized linear mixed model. Covariates with p < 0.10 and clinical relevance were included in multivariable models. Results: The prophylaxis group showed significantly fewer ABEs (incidence rate ratio [IRR]: 0.383, p = 0.011). Each 100 IU/kg monthly dose increment reduced bleed risk (IRR: 0.692, p < 0.001). Adherence showed no independent association with bleeding in adjusted models. Conclusions: Bleed prevention in haemophilia B is driven more by delivered FIX exposure than by regimen label. Study-defined sustained prophylaxis remains underused and under-dosed. Individualized dosing and continuous adherence monitoring are essential to close this treatment gap and improve outcomes.
- 26 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4555
Open AccessCharacteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX
Introduction: In Haemophilia B, guideline-level factor IX (FIX) prophylaxis is recommended, but real-world dosing and adherence vary. Aim: To assess treatment patterns, adherence, FIX dosing, and their associations with bleeding events in Korean patients. Methods: We conducted a retrospective chart review and one-time survey of 130 Korean patients with haemophilia B treated with FIX for ≥12 months at 12 centers (June 2022–May 2023). A total of forty-seven patients (36.2%) received prophylaxis (≥90 IU/kg/week for ≥45 weeks); the remainder were managed non-prophylactically. Annualized bleeding events (ABEs) were analyzed using negative binomial regression, and monthly bleeds with a generalized linear mixed model. Covariates with p < 0.10 and clinical relevance were included in multivariable models. Results: The prophylaxis group showed significantly fewer ABEs (incidence rate ratio [IRR]: 0.383, p = 0.011). Each 100 IU/kg monthly dose increment reduced bleed risk (IRR: 0.692, p < 0.001). Adherence showed no independent association with bleeding in adjusted models. Conclusions: Bleed prevention in haemophilia B is driven more by delivered FIX exposure than by regimen label. Study-defined sustained prophylaxis remains underused and under-dosed. Individualized dosing and continuous adherence monitoring are essential to close this treatment gap and improve outcomes.
- Open Access
- 1 January 2006
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 49 (11) , 1223-1226
Pyridoxine responsive sideroblastic anemia in a boy with mitral valve prolapse
- 1 January 2006
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 49 (11) , 1223-1226
Open AccessPyridoxine responsive sideroblastic anemia in a boy with mitral valve prolapse
- Open Access
- 1 January 2006
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 49 (6)
Analysis of causative microorganisms and choice of antibiotics according to the onset of neonatal sepsis
- 1 January 2006
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 49 (6)
Open AccessAnalysis of causative microorganisms and choice of antibiotics according to the onset of neonatal sepsis
- Open Access
- 1 January 2006
- Published by Springer Nature in The Korean Journal of Hematology
- Vol. 41 (4) , 235-242
Current Status of Hematopoietic Stem Cell Transplantation in Korean Children
- 1 January 2006
- Published by Springer Nature in The Korean Journal of Hematology
- Vol. 41 (4) , 235-242
Open AccessCurrent Status of Hematopoietic Stem Cell Transplantation in Korean Children
- Open Access
- 20 July 2000
- Published by Wiley in American Journal of Hematology
- Vol. 64 (4) , 303-305
Rubella‐associated aplastic anemia treated by syngeneic stem cell transplantations
- 20 July 2000
- Published by Wiley in American Journal of Hematology
- Vol. 64 (4) , 303-305
Open AccessRubella‐associated aplastic anemia treated by syngeneic stem cell transplantations
- Open Access
- 15 June 2000
- Published by Wiley in American Journal of Hematology
- Vol. 64 (3) , 218-220
Ruptured Klebsiella pneumoniae liver abscess after high‐dose cyclophosphamide for severe aplastic anemia
- 15 June 2000
- Published by Wiley in American Journal of Hematology
- Vol. 64 (3) , 218-220
Open AccessRuptured Klebsiella pneumoniae liver abscess after high‐dose cyclophosphamide for severe aplastic anemia